GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Foxo Technologies FOXO · USD

Information Technology · US listing · 🇺🇸 United States

Compare

0.19

+90.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Foxo Technologies

From its filings with the US Securities and Exchange Commission

SEC filings

Foxo Technologies is based in West Palm Beach, Florida and is incorporated in Delaware. Its shares trade on OTC under the ticker FOXO. The SEC classifies its business as commercial physical & biological research. In the fiscal year to 31 December 2025, it reported revenue of $16.4m and a net loss of $12.4m. At that date it held total assets of $44.6m and shareholders' equity of $11.1m.

In its own words

Healthcare segment began with the acquisition of Myrtle on June 14, 2024, and includes RCHI, which was acquired on September 10, 2024.

BSF expanded its clinical capabilities through the addition of tele-specialty services and cardiac diagnostics.

Company seeks to conduct its business in compliance with all statutes, regulations, and other requirements applicable to its operations.

Quoted from its 10-K, filed 15 Apr 2026. Read the filing on SEC.gov ↗

Company facts

Sector
Information Technology
Industry
Software
Listed since
11 Dec 2020
Employees
24
Head office
477 SOUTH ROSEMARY AVENUE, WEST PALM BEACH, FL, 33401
Incorporated in
DE
Classification
Services-Commercial Physical & Biological Research
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Bret BarnesIndependent Chairman of the Board$744,080
  • Mr. Seamus LaganChief Executive Officer, Director, since 2024
  • Ms. Sylwia HaumanChief Financial Officer
  • Mr. Trevor LangleyDirector
  • Mr. Francis DewolfIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company employs 24 full-time staff members.
  • It utilizes artificial intelligence for DNA methylation analysis.
  • Two distinct business segments support its operations.

Weaknesses

  • The firm is classified as a biotechnology company.
  • Operations are limited to the Minneapolis headquarters.
  • Only 24 employees work for the organization.

Opportunities

  • Commercializing epigenetic biomarkers for life insurance.
  • Developing saliva-based health and wellness solutions.
  • Transforming the value proposition for insurance carriers.

Threats

  • The source description contains conflicting industry classifications.
  • Data reliability is compromised by untrusted facts.
  • Contradictions exist between technology and biotech labels.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.